How were Nightstar Therapeutics' earnings last quarter?

Nightstar Therapeutics PLC (NASDAQ:NITE) issued its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.13.

What other stocks do shareholders of Nightstar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nightstar Therapeutics investors own include Cronos Group (CRON) , Portola Pharmaceuticals (PTLA) , Sorrento Therapeutics (SRNE) , Ligand Pharmaceuticals (LGND) , OncoMed Pharmaceuticals (OMED) , Neurocrine Biosciences (NBIX) , NVIDIA (NVDA) , Sangamo Therapeutics (SGMO) and Supernus Pharmaceuticals (SUPN) .

When did Nightstar Therapeutics IPO?

Nightstar Therapeutics (NITE) raised $76 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

NASDAQ:NITE

Nightstar Therapeutics (NITE) Stock Price, News & Analysis

→ The only accurate crypto trading system I know … (From Weiss Ratings) (Ad)

Free NITE Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $25.41
▼
$25.41
50-Day Range: $25.41
▼
$25.41
52-Week Range: $9.59
▼
$29.55

Volume: 40 shs
Average Volume: 185,808 shs
Market Capitalization: $852.25 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Nightstar Therapeutics alerts:

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Nightstar Therapeutics Stock (NASDAQ:NITE)

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

Click here to find out that this 8,788% cryptocurrency is.

NITE Stock News Headlines

November 12, 2023 | bbc.co.uk

Thank you for supporting The Big Night In

November 1, 2023 | usatoday.com

Bills vs. Giants Sunday Night Football highlights: Buffalo survives for late win

April 20, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

October 14, 2023 | yahoo.com

Early bird vs. night owl — is one really healthier than the other? Here's what research shows.

September 14, 2023 | usatoday.com

Justin Timberlake, Timbaland curating music for 'Monday Night Football'

September 10, 2023 | usatoday.com

Who is playing in NFL Sunday Night Football? Here's the complete 2023 SNF schedule

June 24, 2023 | sfgate.com

Disneyland’s first-ever Pride Nite was one of the best nights I’ve ever had in the park

June 13, 2023 | forbes.com

Best Night Guards (Mouth Guards) For Teeth Grinders Of 2023

April 20, 2024 | Paradigm Press (Ad)

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

May 29, 2023 | usatoday.com

NFL owners approve flexing of 'Thursday Night Football' games

May 16, 2023 | bbc.co.uk

Day and night

May 11, 2023 | bbc.co.uk

Last Night tickets information

February 8, 2023 | msn.com

The Night Agent Adaptation From Shield Creator Shawn Ryan Gets Netflix Release Date and Teaser — Watch

January 27, 2023 | yahoo.com

M. Night Shyamalan’s Knock At The Cabin Has Screened, See What People Are Saying About The Apocalyptic Thriller

October 25, 2022 | thetimes.co.uk

Syncona puts cash on table for gene therapy group deal

August 21, 2022 | thestreet.com

Nightstar Therapeutics plc Sponsored ADR News

July 6, 2022 | investing.com

NITE_old Historical Data

January 6, 2022 | sg.finance.yahoo.com

Sensorion appoints Aniz Girach as Independent Board Member

See More Headlines

Receive NITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nightstar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological Products, Except Diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:NITE
CUSIP: N/A
CIK: 1711675
Web: www.nightstartx.com
Phone: 44-20-7062-2777
Fax: N/A
Employees: 47
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.26)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -30.89%
Return on Assets: -27.65%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.54
Quick Ratio: 8.54

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.89 per share
Price / Book: 4.31

Miscellaneous

Outstanding Shares: 33,540,000
Free Float: N/A
Market Cap: $852.25 million
Optionable: Not Optionable
Beta: 2.84

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. David Fellows (Age 62)
CEO & Director
Mr. Senthil Vel Sundaram (Age 41)
Chief Financial Officer
Dr. Gregory Scott Robinson (Age 60)
Chief Scientific Officer
Brian Luque
Sr. Mang. of Investor Relations
Mr. Seokho Bryan Yoon Esq. (Age 40)
Gen. Counsel & Sec.

Key Competitors

View All Competitors

NITE Stock Analysis - Frequently Asked Questions

How were Nightstar Therapeutics' earnings last quarter?: Nightstar Therapeutics PLC (NASDAQ:NITE) issued its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.13.
What other stocks do shareholders of Nightstar Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Nightstar Therapeutics investors own include Cronos Group (CRON), Portola Pharmaceuticals (PTLA), Sorrento Therapeutics (SRNE), Ligand Pharmaceuticals (LGND), OncoMed Pharmaceuticals (OMED), Neurocrine Biosciences (NBIX), NVIDIA (NVDA), Sangamo Therapeutics (SGMO) and Supernus Pharmaceuticals (SUPN).
When did Nightstar Therapeutics IPO?: Nightstar Therapeutics (NITE) raised $76 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.

This page (NASDAQ:NITE) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Nightstar Therapeutics (NITE) Stock Price, News & Analysis

About Nightstar Therapeutics Stock (NASDAQ:NITE)

NITE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

NITE Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info